Pyrazole Derivatives as DLK Inhibitors for Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's are inadequate, and there is a pressing need for effective inhibitors of Dual Leucine Zipper Kinase (DLK) to address neuronal cell death and degeneration.
Innovation Solution
Development of novel organic compounds, specifically defined by their structural formulas, which act as inhibitors of DLK to prevent or slow down neurodegenerative processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative diseases, then existing therapy options are available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent segments the treatment approach by developing a series of compound structures (Formula 1 with various R1A, R1B, R1C, R1D, R2, R3, R4, R5, R6 substituents) that can be differentiated and optimized for specific DLK inhibition needs, allowing selection of appropriate compounds for different neurodegenerative conditions
Solution Approach 2:
The patent applies parameter changes by systematically varying chemical substituents (R groups) on the core pyrazole structure to optimize DLK inhibition potency, selectivity, and metabolic properties, thereby improving treatment effectiveness while maintaining structural diversity
2Reliability
If novel compounds with superior metabolism profiles are developed, then therapeutic benefits are improved, but compound complexity increases
Solution Approach 1:
The patent optimizes metabolism profiles by systematically modifying chemical parameters (substituent types, positions, and combinations) while maintaining the core pyrazole structure, thereby improving therapeutic benefits without excessive complexity increase
Solution Approach 2:
The patent creates composite molecular structures combining the core pyrazole scaffold with various functional groups (R1A, R1B, R1C, R1D, R2, R3, R4, R5, R6 substituents) to achieve superior metabolism profiles through synergistic structural combinations
Data Source
AI summary
The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.